Free Trial

Xenetic Biosciences (XBIO) Competitors

$3.96
+0.24 (+6.45%)
(As of 03:26 PM ET)

XBIO vs. FWBI, ENVB, LIXT, PCSA, KA, ADIL, LIPO, HOTH, HILS, and AIMD

Should you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include First Wave BioPharma (FWBI), Enveric Biosciences (ENVB), Lixte Biotechnology (LIXT), Processa Pharmaceuticals (PCSA), Kineta (KA), Adial Pharmaceuticals (ADIL), Lipella Pharmaceuticals (LIPO), Hoth Therapeutics (HOTH), Hillstream BioPharma (HILS), and Ainos (AIMD). These companies are all part of the "pharmaceutical preparations" industry.

Xenetic Biosciences vs.

Xenetic Biosciences (NASDAQ:XBIO) and First Wave BioPharma (NASDAQ:FWBI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Xenetic Biosciences received 164 more outperform votes than First Wave BioPharma when rated by MarketBeat users. Likewise, 68.24% of users gave Xenetic Biosciences an outperform vote while only 45.45% of users gave First Wave BioPharma an outperform vote.

CompanyUnderperformOutperform
Xenetic BiosciencesOutperform Votes
174
68.24%
Underperform Votes
81
31.76%
First Wave BioPharmaOutperform Votes
10
45.45%
Underperform Votes
12
54.55%

In the previous week, First Wave BioPharma had 4 more articles in the media than Xenetic Biosciences. MarketBeat recorded 4 mentions for First Wave BioPharma and 0 mentions for Xenetic Biosciences. First Wave BioPharma's average media sentiment score of 1.24 beat Xenetic Biosciences' score of 0.00 indicating that First Wave BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Xenetic Biosciences Neutral
First Wave BioPharma Positive

First Wave BioPharma has a consensus price target of $36.00, suggesting a potential upside of ∞. Given First Wave BioPharma's higher probable upside, analysts clearly believe First Wave BioPharma is more favorable than Xenetic Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenetic Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
First Wave BioPharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Xenetic Biosciences has a beta of 2.56, suggesting that its stock price is 156% more volatile than the S&P 500. Comparatively, First Wave BioPharma has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 12.3% of First Wave BioPharma shares are owned by institutional investors. 9.0% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 0.5% of First Wave BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

First Wave BioPharma has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -182.99%. Xenetic Biosciences' return on equity of -43.40% beat First Wave BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Xenetic Biosciences-182.99% -43.40% -40.03%
First Wave BioPharma N/A -102.83%-22.74%

Xenetic Biosciences has higher revenue and earnings than First Wave BioPharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xenetic Biosciences$2.54M2.39-$4.14M-$2.93-1.34
First Wave BioPharmaN/AN/A-$15.80MN/AN/A

Summary

Xenetic Biosciences beats First Wave BioPharma on 8 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XBIO vs. The Competition

MetricXenetic BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.07M$6.97B$5.07B$8.02B
Dividend YieldN/A2.73%2.80%3.91%
P/E Ratio-1.3410.80126.3514.91
Price / Sales2.39225.692,500.8376.02
Price / CashN/A35.7235.3532.25
Price / Book0.705.465.444.63
Net Income-$4.14M$147.24M$104.00M$213.35M
7 Day Performance-0.39%1.15%0.31%0.41%
1 Month Performance4.23%4.73%4.22%5.44%
1 Year Performance39.22%-5.88%4.99%8.72%

Xenetic Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FWBI
First Wave BioPharma
1.5769 of 5 stars
$2.98
-0.3%
$118.00
+3,859.7%
N/A$6.05MN/A-0.019
ENVB
Enveric Biosciences
2.4476 of 5 stars
$0.82
-2.4%
$10.00
+1,118.8%
-76.6%$5.98MN/A-0.107Gap Down
LIXT
Lixte Biotechnology
0 of 5 stars
$2.64
-1.1%
N/A-58.4%$5.94MN/A-1.133Gap Up
PCSA
Processa Pharmaceuticals
3.0206 of 5 stars
$2.18
-1.8%
$8.00
+267.0%
-85.6%$6.24MN/A-0.4413Positive News
KA
Kineta
2.1458 of 5 stars
$0.52
flat
$8.00
+1,438.5%
-84.5%$5.90M$5.44M-0.3811
ADIL
Adial Pharmaceuticals
0.3383 of 5 stars
$1.44
-0.7%
N/A-82.5%$5.86MN/A-0.254Positive News
Gap Down
LIPO
Lipella Pharmaceuticals
3.4318 of 5 stars
$0.76
+4.1%
$2.00
+162.1%
-61.5%$5.81M$450,000.000.005News Coverage
HOTH
Hoth Therapeutics
2.3003 of 5 stars
$1.18
-3.3%
$4.00
+239.0%
-26.5%$5.77MN/A-0.252Positive News
HILS
Hillstream BioPharma
0 of 5 stars
$0.36
-2.7%
N/A+1.6%$6.42MN/A-0.511
AIMD
Ainos
0 of 5 stars
$1.04
-1.9%
N/AN/A$6.51M$122,112.00-0.4146

Related Companies and Tools

This page (NASDAQ:XBIO) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners